Introduction
Hypothyroidism is a common thyroid disorder affecting about 3-5% of the general population [1, 2] . Treatment includes thyroid hormone-replacement therapy, and levothyroxine (thyroxine sodium) is the treatment of choice for maintenance. Patients usually respond well to treatment and the dose is usually monitored in response to a combination of patients' symptoms and thyroidstimulating hormone (TSH) serum levels [3] .
Genome-wide association studies (GWAS) have found association signals with hypothyroidism and serum TSH levels [4] [5] [6] . However, replication studies are scarce and desirable to help ensure that a genotype-phenotype association observed in a GWAS represents a credible association. Replication of an association requires genotyping the initially discovered genetic variant in a completely independent sample of sufficient size [7] .
Recently, electronic medical records (EMRs)-derived phenotypes have been linked to genetic biobanks to allow research on the genetic basis of a wide range of traits highly cost effectively [8] . Therefore, such EMRlinked biobanks might be appropriate to investigate the role that genetics play in thyroid-related disorders.
Using the Genetics of Diabetes and Audit Research
Tayside Study (GoDARTS) data set, we aimed to replicate the association of selected GWAS-identified loci with the diagnosis of hypothyroidism and with average serum TSH levels in a Scottish population.
Patients and methods
A cross-sectional study was carried out among patients from the GoDARTS population recruited in Tayside, Scotland (UK). All participants in this population are of white ethnicity and have been described previously elsewhere [9] . Each patient has a unique patient identification number (Community Health Index) that facilitates anonymous data linkage across all available EMRs by the Health Informatics Centre of the University of Dundee (http://www.dundee.ac.uk/hic). Records on redeemed drug prescriptions, demography and biochemistry, and several databases were linked to genetic data. Databases included the Scottish Care Information-Diabetes Collaboration, the Scottish Morbidity Records (hospital admissions and cancer registry), radioiodine and the Office of Population Censuses and Surveys Classification of Surgical Operations version 4 (OPCS4).
Phenotype definition criteria
All patients with at least one serum TSH recording between 1994 and 2014 were considered for inclusion in this study. A phenotype of all-cause hypothyroidism (i.e. cases) was defined as having been issued at least two prescriptions for thyroid-replacement therapy [British National Formulary codes (BNF) 6.2.1] during the study period. Controls never received a prescription for thyroidreplacement therapy or received just one.
Patients with a history of thyroid cancer or probable hyperthyroidism were excluded. Probable hyperthyroidism was considered as having at least one OPCS4 code of treatment with thyroid surgery (OPCS4: B08, B09, B12), radioactive iodine and/or a prescription of antithyroid drug use (BNF 6.2.2). At least one International Classification of Diseases (ICD) 9th-10th edition code (ICD9: 193; ICD10: C73, D093, D440) was required for thyroid cancer.
The TSH (average) was taken as the median of serum TSH measures recorded throughout the study period for each patient. Euthyroid individuals had a normal average TSH serum level (defined as 0.4-4.0 mIU/l) and never received thyroid medication.
Genetic data
Genotype data were available from the following platforms: the Human Exome-12 via ChIP, the MetaboChip [10] , Illumina HumanOmni Express-12VI platform (Illumina, San Diego, California, USA), Affymetrix 6.0 platform (Affymetrix Inc., Santa Clara, California, USA) and the Illumina Infinium custom GWAS chip (Illumina). Imputation was performed against the 1000 Genomes Phase I V3 reference panel using Impute2 [11] and using the haplotype reference consortium [12] ; calls made with imputation quality below 90% were discarded. All single-nucleotide polymorphisms (SNPs) were in Hardy-Weinberg equilibrium (P < 10e − 04).
Selection of genetic loci to be tested
Association signals reported by latest powered GWAS on hypothyroidism [4, 5] and serum TSH levels [6] .
Statistical analysis
Analysis of variance and χ 2 -tests were used to compare the means and frequencies among groups of patients, respectively, and nonparametric tests were used where appropriate [13] . Single-locus tests of association with hypothyroidism (coded as binary) were performed on cases and controls by logistic regression under the assumption of an additive genetic model. Odds ratios (OR) from logistic models were adjusted for age at first TSH recording and sex. Linear regression models were used on euthyroid individuals to test the association with average serum TSH levels and to estimate the proportion of variation of TSH explained by the SNPs. Fixed-effects meta-analyses were carried out to assess the consistency of effects of this study with the previously reported ones, and heterogeneity was quantified using the I-squared measure [14] . Statistical analyses were carried out using Stata/SE version 13.1 software (StataCorp, College Station, Texas, USA) and the statistical significance level was set at P value less than 5e − 0.2. The significance threshold was further adjusted with Bonferroni correction for the number of independent SNPs was tested simultaneously.
Ethical approval
All analyses were carried out on anonymized data sets. The study was approved by the Tayside Medical Ethics Committee and informed consent was obtained from all participants.
Results
We identified 16 464 individuals as being eligible for the study, of whom 2484 had hypothyroidism (cases) and 13 980 did not (controls), and up to 11 160 (i.e. 1703 cases and 9457 controls) had available genomic data in the GoDARTS biobank. Compared with controls, cases were mostly women (73 vs. 43.4%, P < 1e − 03) and had a higher average serum TSH level (2.2 vs. 1.7 mIU/l, P < 1e − 03), but there was no difference in age (57 years). Table 1 shows the adjusted ORs for SNPs associated with hypothyroidism that were identified through published GWAS. All four SNPs located on chromosome 9 at FOXE1 (rs965513, rs10759944, rs925489 and rs7850258) were associated with hypothyroidism at P value less than 5e − 08 with similar effect estimates (OR = 0.75-0.76). These four SNPs were in strong linkage disequilibrium (LD) (r 2 > 0.99). An additional fifth polymorphism near FOXE1 (rs1877432) did not reach statistical significance. We did not find an association for several SNPs located on the same chromosome at DFNB31 (rs1535971, rs4979402, rs4979397 and rs1408528). In addition to the associations found on chromosome 9 at FOXE1, we found significant associations on chromosome 1 at PTPN22 (rs6679677 and rs2476601; P < 1.9e − 03).
Within the control group, there were 9125 (i.e. 96% of the controls) euthyroid individuals aged 57.4 years 43.4% were women, and had an average serum TSH level of 1.72 mIU/l. For serum TSH concentration in this subgroup (Table 2) , we confirmed 12 out of 20 statistically significant SNPs reported previously at PDE8B, CAPZB, PDE10A, LOC105371356, NR3C2, VEGFA, IGFBP5, INSR, PRDM11, NFIA, ITPK1 and ABO; the coded allele was associated with increased TSH in five of them (PDE10A, LOC105371356, NR3C2, IGFBP5 and ABO). Each copy of the coded allele of rs6885099 at PDE8B (phosphodiesterase type 8B) was associated with a decrease of 0.13 mIU/l serum TSH. This SNP accounted for 1.46% of serum TSH variation, followed by signals in the capping protein -actin filament muscle Z-line β (CAPZB-rs10799824) and the phosphodiesterase type 10A (PDE10A-rs753760) that contributed towards 0.74 and 0.71% of variation, respectively. Further adjustment of regression models for age and sex did not change the size and direction of the effect estimates. When combined, the 12 significantly associated SNPs accounted for 6.47% (n = 5241, P < 1e − 04) of the TSH variation, which increased to 6.83% after also including age and sex as predictors in the linear model, thus leaving 0.36% (i.e.
6.83-6.47%) of the variation to age and sex. Male sex was associated with a lower serum TSH (β = − 0.052, P = 1.2e − 02) and each additional year of life conferred an increase of 0.003 mIU/l serum TSH (P = 1.2e − 04).
The consistency of SNPs effects of this study with the previously reported studies is shown in Figs 1 and 2. Heterogeneity was quantified using the I-squared measure, and a value of 0% (i.e. no observed heterogeneity) was obtained in almost all meta-analyses. Although no significant heterogeneity was detected, a value close to 50% was found in two of the meta-analyses (Fig. 1 , PTPN22-rs2476601 on hypothyroidism; Fig. 2 , ABO-rs657152 on average serum TSH).
Discussion
This was a record-linkage study using electronic databases to validate novel genetic loci discovered in GWA studies with hypothyroidism and serum TSH levels in a Scottish Caucasian population from the GoDARTS database.
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because they did not differ from the rest of the controls. There were 252 of these patients in the control group who had normal TSH values (1.730 mIU/l) similar to controls who never received replacement therapy (1.735 mIU/l). Besides, their inclusion could not result in underestimation of the genetic association effects because they represent less than 3% of the controls. Thus, we found no reason to exclude them.
Four SNPs in LD at FOXE1 (thyroid transcription factor 2) were replicated in this study with hypothyroidism, the strongest being rs965513. Loci in HLA, SH2B3, PTPN22, CTLA4, PDE8B and VAV3 were also replicated. The association between FOXE1 and hypothyroidism was first reported by Denny et al. [4] in a GWAS of 1317 cases and 5053 controls identified from EMRs and subsequently by Eriksson et al. [5] in the largest GWAS to date of hypothyroidism of 3736 cases and 35 546 controls of European ancestry. Some of these genes have known immune functions (HLA, SH2B3, PTPN22, CTLA4 and VAV3) and others in thyroid function (FOXE1, CAPZB and PDE8B). Our associations consistently replicate the effect size and direction of these loci, despite slightly different phenotypes reported by others. Denny et al. [4] searched EMRs for the presence of a thyroidreplacement medication for at least 3 months and at least one ICD code for hypothyroidism. Eriksson et al. [5] used self-administered web-based questionnaires for phenotype identification; cases were those who answered 'yes' to hypothyroidism or to elevated TSH levels or to taking medication for hypothyroidism. We did not query ICD codes for phenotype definition as this would have missed the majority of cases with hypothyroidism who did not have a hospital admission.
Porcu et al. [6] carried out an analysis of 26 420 participants pooled from 18 cohorts to identify novel loci related to serum TSH. Before GWAS, they had excluded those with thyroid pathologies, thyroid surgery and/or thyroid medication, as well as those with levels beyond the normal TSH range. Overall, their 20 reported loci explained 5.6% of TSH variation in euthyroid individuals. Our study confirmed 12 of these reported associations, which combined accounted for a larger serum TSH variation (6.5%). As expected, male sex was associated with a lower serum TSH [15] . We acknowledge that the higher variance observed from fewer variants could be because of our smaller sample size (as compared to Porcu et al. [6] ). However, the allele frequency from our study (see Table 2 ) did not differ from that reported by Porcu et al. [6] . It is plausible that as the causal variants have still not been confirmed through functional studies, the Scottish Caucasian population shows a different LD structure between these common SNPs and the causal variants. However, given the lack of differences in TSH levels between the compared populations (i.e. 1.73mIU/l of GoDARTS populations and 1.78 mIU/l of Porcu et al.'s [6] populations), this would be unlikely.
The meta-analyses of the association test results between significant SNPs and hypothyroidism or serum TSH observed across studies indicate that variability between estimated effects from this current study and the previously reported ones can be explained by chance only.
In summary, EMR-linked genomic data enabled replication of discovered genes associated with several traits without additional genotyping costs. Replication confirmed at genome-wide significance the association of loci in FOXE1 with hypothyroidism, and PDE8B, CAPZB and PDE10A with serum TSH. The GoDARTS database seems to be appropriate for research on genetic associations of thyroid traits and the identified set of SNPs explains nearly 7% of variation in serum TSH concentration.
